Literature DB >> 14711073

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.

William A Craig1.   

Abstract

Time above MIC for free drug concentrations is the important PK-PD parameter correlating with the efficacy of beta-lactam antibiotics. The duration of time plasma concentrations needed to exceed the MIC is relatively similar for most organisms except staphylococci. Neutrophils contribute very little to the overall activity of beta-lactams. The appearance of increasing antimicrobial resistance can challenge the efficacy of these drugs when concentrations do not exceed the MIC for 40% to 50% of the dosing interval. Time above MIC with oral amoxicillin and amoxicillin-clavulanate can be enhanced with high-dose formulations. Time above MIC with parenteral preparations can be enhanced by longer intravenous infusions or even continuous infusion. The 24-hour AUC-MIC is probably the important PK-PD parameter correlating with the efficacy of vancomycin and teicoplanin. It clearly is the important parameter for the efficacy of linezolid. Usual doses of these drugs generally provide adequate plasma concentrations to treat effectively infections in which plasma concentrations are predictive of tissue concentrations. Penetration of these drugs into respiratory secretions, such as ELF, is enhanced for linezolid and reduced for vancomycin. This may give linezolid an advantage over vancomycin in certain respiratory infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14711073     DOI: 10.1016/s0891-5520(03)00065-5

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  150 in total

1.  Effect of ertapenem protein binding on killing of bacteria.

Authors:  David E Nix; Kathryn R Matthias; Emily C Ferguson
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.

Authors:  Anthony M Nicasio; Jürgen B Bulitta; Thomas P Lodise; Rebecca E D'Hondt; Robert Kulawy; Arnold Louie; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

3.  Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.

Authors:  J C Bader; E A Lakota; G E Dale; H S Sader; J H Rex; P G Ambrose; S M Bhavnani
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

4.  Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.

Authors:  Ken Coleman; Premavathy Levasseur; Anne-Marie Girard; Monica Borgonovi; Christine Miossec; Henri Merdjan; George Drusano; David Shlaes; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

5.  Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.

Authors:  Henry S Heine; Arnold Louie; Jeffrey J Adamovicz; Kei Amemiya; Randy L Fast; Lynda Miller; Steven M Opal; John Palardy; Nicolas A Parejo; Fritz Sörgel; Martina Kinzig-Schippers; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

6.  Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.

Authors:  Alexander A Vinks; Ronald N van Rossem; Ron A A Mathôt; Harry G M Heijerman; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.

Authors:  Johan W Mouton; Nieko Punt; Alexander A Vinks
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

8.  Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.

Authors:  K N Williams; C K Stover; T Zhu; R Tasneen; S Tyagi; J H Grosset; E Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

9.  A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.

Authors:  Stéphanie Leroux; Jean-Michel Roué; Jean-Bernard Gouyon; Valérie Biran; Hao Zheng; Wei Zhao; Evelyne Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

10.  Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.

Authors:  Alex Soriano; Mar Ortega; Sebastián García; Georgina Peñarroja; Albert Bové; Miguel Marcos; Juan C Martínez; José A Martínez; Josep Mensa
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.